Novartis Secures FDA Approval for Afinitor: New Hope for Kidney Cancer Patients

March 31, 2009

(ChattahBox)-Swiss drug maker, Novartis AG secured approval for its promising new cancer drug, Afinitor today, also known as RAD001, which is expected to extend the life of many patients suffering from advanced kidney cancer. The drug was approved for use on kidney cancer patients as a treatment of last resort, after standard treatments have been tried and failed.

Kidney cancer or renal cell carcinoma, affects 32,000 Americans every year, with 13,000 sufferers losing their battle with the disease. Patients with advanced kidney cancer, before today’s approval of Afinitor, faced limited treatment options, told by their doctors’ to spend their remaining days with family members and to put their affairs in order.

Previous drug trials showed that Afinitor significantly lessened tumor growth and reduced the risk of disease progression by 70 percent. Afinitor is in a class of drugs called, targeted therapies that work by inhibiting the growth of the protein mTOR, which regulates tumor cell division and the growth of blood vessels in cancer cells.

Novartis AG expects the drug to show potential to benefit other types of cancer such as, lymphoma, breast, gastric and lung cancer. Afinitor has fewer side effects than chemotherapy, and it is easy to administer, with patients needing just a once daily, oral therapy.

Novartis is expected to earn more than $1 billion in annual sales from Afinitor. More importantly, thousands of people suffering from advanced kidney cancer will gain a new lease on life. Every extra day of life is precious to someone who was counting off their remaining weeks left of life on the fingers of one hand.

Source


Comments

One Response to “Novartis Secures FDA Approval for Afinitor: New Hope for Kidney Cancer Patients”

  1. 100 100 answer answer cancer lung question question | Lung Cancer Reviewed on April 1st, 2009 11:20 am

    […] (ChattahBox)-Swiss drug maker, Novartis AG secured approval for its promising new cancer drug, Afinitor today, also known as RAD001, which is expected to extend the life of many patients suffering from advanced kidney cancer. The drug was approved More Lung Cancer News […]

Got something to say? **Please Note** - Comments may be edited for clarity or obscenity, and all comments are published at the discretion of ChattahBox.com - Comments are the opinions of the individuals leaving them, and not of ChattahBox.com or its partners. - Please do not spam or submit comments that use copyright materials, hearsay or are based on reports where the supposed fact or quote is not a matter of public knowledge are also not permitted.